Drug Development.

Area of Science:

• Neuroscience
• Microbiology
• Genetics

Background:

• Cell-to-cell transmission of misfolded proteins, like alpha-synuclein (α-syn) in Parkinson's disease (PD), contributes to neurodegeneration.
• Gut microbiota-derived metabolites are investigated for their potential to attenuate α-syn misfolding and promote resilience against PD phenotypes.

Purpose of the Study:

• To investigate the neuroprotective effects of six gut microbiota-derived compounds against protein misfolding and neurodegeneration.
• To assess the efficacy of these compounds in both in vitro and in vivo models relevant to PD and other neurodegenerative disorders.

Main Methods:

• In vitro protein aggregation assays (e.g., thioflavin-T, electron microscopy) were used to evaluate the inhibitory effects of compounds on α-syn and β-amyloid aggregation.
• A Drosophila model overexpressing GGGGCC hexanucleotide repeats (linked to PD, ALS, FTD) was used to test the in vivo neuroprotective capabilities of the compounds.

Main Results:

• Three compounds (GMP26, GMP44, GMP28) potently inhibited α-syn and β-amyloid aggregation in vitro.
• All six compounds significantly suppressed neurodegeneration in the Drosophila model at 10 µM, with GMP26 and GMP11 showing near-complete suppression.
• The efficacy ranking was GMP26 = GMP11 > GMP39 > GMP10 > GMP44 > GMP28.

Conclusions:

• Gut microbiota metabolites can modulate mechanisms underlying neurodegenerative diseases.
• Compound GMP26 shows promise for simultaneously targeting α-syn misfolding and C9orf72 expansion, potentially benefiting patients with PD, ALS, and FTD.